Regadenoson meets Phase III endpoint

CV Therapeutics (CVTX) and Astellas (Tokyo:4503) said regadenoson ( CVT-3146) met the primary endpoint of comparability with Adenoscan in an international double-blind Phase III trial in 784 patients ...